Faculty Opinions recommendation of Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.720488787.793501270 ◽

2014 ◽

Author(s):

Minesh Mehta ◽

Manmeet Ahluwalia

Keyword(s):

Brain Metastases ◽

Phase 2 ◽

Phase 2 Trial ◽

Open Label Phase

Download Full-text

Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(20)30111-x ◽

2020 ◽

Vol 21 (5) ◽

pp. 655-663 ◽

Author(s):

Sarah B Goldberg ◽

Kurt A Schalper ◽

Scott N Gettinger ◽

Amit Mahajan ◽

Roy S Herbst ◽

...

Keyword(s):

Brain Metastases ◽

Long Term Results ◽

Phase 2 ◽

Phase 2 Trial ◽

Biomarker Analysis ◽

Open Label Phase

Download Full-text

Faculty Opinions recommendation of Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726401484.793552506 ◽

2018 ◽

Author(s):

Minesh Mehta

Keyword(s):

Lung Cancer ◽

Brain Metastases ◽

Small Cell Lung Cancer ◽

Phase 2 ◽

Early Analysis ◽

Small Cell Lung ◽

Phase 2 Trial ◽

Open Label Phase

Download Full-text

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(16)30053-5 ◽

2016 ◽

Vol 17 (7) ◽

pp. 976-983 ◽

Author(s):

Sarah B Goldberg ◽

Scott N Gettinger ◽

Amit Mahajan ◽

Anne C Chiang ◽

Roy S Herbst ◽

...

Keyword(s):

Lung Cancer ◽

Brain Metastases ◽

Small Cell Lung Cancer ◽

Phase 2 ◽

Early Analysis ◽

Small Cell Lung ◽

Phase 2 Trial ◽

Open Label Phase

Download Full-text

Faculty Opinions recommendation of Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727696033.793552505 ◽

2018 ◽

Author(s):

Minesh Mehta

Keyword(s):

Brain Metastases ◽

Phase 2 ◽

Phase 2 Trial ◽

Melanoma Brain Metastases ◽

Open Label Phase

Download Full-text

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(12)70090-6 ◽

2012 ◽

Vol 13 (5) ◽

pp. 459-465 ◽

Author(s):

Kim Margolin ◽

Marc S Ernstoff ◽

Omid Hamid ◽

Donald Lawrence ◽

David McDermott ◽

...

Keyword(s):

Brain Metastases ◽

Phase 2 ◽

Phase 2 Trial ◽

Open Label Phase

Download Full-text

Ipilimumab combined with stereotactic radiosurgery in melanoma patients with brain metastases: A multicenter, open label, phase 2 trial.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.9520 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 9520-9520 ◽

Author(s):

Laurent Mortier ◽

Philippe Jamme ◽

Jean Philippe Lacour ◽

Caroline Robert ◽

Thierry Lesimple ◽

...

Keyword(s):

Brain Metastases ◽

Stereotactic Radiosurgery ◽

Phase 2 ◽

Phase 2 Trial ◽

Open Label Phase ◽

Melanoma Patients

Download Full-text

Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30429-1 ◽

2017 ◽

Vol 18 (7) ◽

pp. 863-873 ◽

Author(s):

Michael A Davies ◽

Philippe Saiag ◽

Caroline Robert ◽

Jean-Jacques Grob ◽

Keith T Flaherty ◽

...

Keyword(s):

Brain Metastases ◽

Phase 2 ◽

Phase 2 Trial ◽

Melanoma Brain Metastases ◽

Open Label Phase

Download Full-text

Dose-Adjusted EPOCH Regimen as First-Line Treatment for Non-Hodgkin's Lymphoma with Hemophagocytic Lymphohistiocytosis: A Single-Arm, Open-Label, Phase 2 Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3304299 ◽

2018 ◽

Author(s):

Jin-Hua Liang ◽

Li Wang ◽

Hua-Yuan Zhu ◽

Jun Qian ◽

Hui Liao ◽

...

Keyword(s):

Hemophagocytic Lymphohistiocytosis ◽

Hodgkin's Lymphoma ◽

Line Treatment ◽

Phase 2 ◽

Phase 2 Trial ◽

Non Hodgkin's Lymphoma ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial

The Lancet Respiratory Medicine ◽

10.1016/s2213-2600(20)30362-3 ◽

2021 ◽

Author(s):

Cornedine J de Gooijer ◽

Vincent van der Noort ◽

Jos A Stigt ◽

Paul Baas ◽

Bonne Biesma ◽

...

Keyword(s):

Malignant Mesothelioma ◽

Phase 2 ◽

Phase 2 Trial ◽

Open Label Phase ◽

Line Chemotherapy

Download Full-text

Dexamethasone plus oseltamivir versus dexamethasone in treatment-naive primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial

The Lancet Haematology ◽

10.1016/s2352-3026(21)00030-2 ◽

2021 ◽

Vol 8 (4) ◽

pp. e289-e298 ◽

Author(s):

Lu Sun ◽

Juan Wang ◽

Linlin Shao ◽

Chenglu Yuan ◽

Hongguo Zhao ◽

...

Keyword(s):

Immune Thrombocytopenia ◽

Phase 2 ◽

Phase 2 Trial ◽

Primary Immune Thrombocytopenia ◽

Open Label Phase ◽

Treatment Naïve

Download Full-text